APA (7th ed.) Citation

Yuankai Shi, Gongyan Chen, Xiang Wang, Yunpeng Liu, Lin Wu, Yanrong Hao, . . . Nan Ge. (2024). Patient-reported outcomes for the phase 3 FURLONG study of furmonertinib versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small cell lung cancerResearch in context. Elsevier.

Chicago Style (17th ed.) Citation

Yuankai Shi, et al. Patient-reported Outcomes for the Phase 3 FURLONG Study of Furmonertinib Versus Gefitinib as First-line Therapy for Chinese Patients with Locally Advanced or Metastatic EGFR Mutation-positive Non-small Cell Lung CancerResearch in Context. Elsevier, 2024.

MLA (9th ed.) Citation

Yuankai Shi, et al. Patient-reported Outcomes for the Phase 3 FURLONG Study of Furmonertinib Versus Gefitinib as First-line Therapy for Chinese Patients with Locally Advanced or Metastatic EGFR Mutation-positive Non-small Cell Lung CancerResearch in Context. Elsevier, 2024.